<p>纽约，2026 年 1 月 22 日（全球新闻稿）——Psyence Biomedical Ltd.（纳斯达克：PBM）（“ <strong>Psyence BioMed</strong>” 或 “ <strong>公司</strong>”）今天宣布，已将其年度及特别股东会议（“ <strong>会议</strong>”）延期至 2026 年 2 月 12 日。</p>
<p>会议将于 2026 年 2 月 12 日上午 9:00（纽约时间）/下午 4:00（开普敦时间）在南非开普敦观察区 Gogosoa 街 51 号，Riverlands，办公大楼 4，Venture Workspace Riverlands 举行。</p>
<p>此次延期是由于未达到召开会议所需的股东法定人数。公司正在与其代理人合作，以确保在 2026 年 2 月 12 日重新召开的会议上达到法定人数。有关会议业务的详细信息，请参见公司于 2026 年 1 月 2 日提交的会议通知和管理信息通函，已在 EDGAR 上备案。请注意，会议的记录日期，即 2025 年 12 月 23 日的营业结束时间，未发生变化。</p>
<p><strong>关于 Psyence BioMed</strong></p>
<p>Psyence Biomedical Ltd.（纳斯达克：PBM）是少数几家专注于迷幻药物治疗的多资产、垂直整合的生物制药公司之一。它是第一家专注于开发自然来源（非合成）迷幻药物（如裸盖菇素和伊波卡因）的生命科学生物技术公司，并在纳斯达克上市。我们致力于解决未满足的心理健康需求。我们承诺采用基于证据的方法，开发安全、有效且获得 FDA 批准的自然来源迷幻治疗，适用于广泛的心理健康障碍。</p>
<p><strong>Psyence Biomedical Ltd.的联系信息</strong> 电子邮件：ir@psyencebiomed.com</p>
<p>媒体咨询：media@psyencebiomed.com</p>
<p>一般信息：info@psyencebiomed.com</p>
<p><strong>投资者联系：</strong> Michael Kydd</p>
<p>投资者关系顾问</p>
<p>michael@psyencebiomed.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本通讯包含 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”。此类声明包括但不限于关于未来财务和运营结果、我们的计划、目标、期望和意图的声明，以及其他以 “可能导致”、“预计”、“将继续”、“预期”、“估计”、“相信”、“打算”、“计划”、“预测”、“展望” 或类似含义的词语标识的声明。</p>
<p>本通讯中的前瞻性声明包括关于会议重新召开的声明及会议的时间（如有）。这些声明基于当前的假设和期望，包括公司将在重新召开的会议上成功获得法定人数的假设。这些假设可能被证明是错误的。不能保证公司能够在重新召开的会议上获得法定人数。存在许多风险和不确定性，可能导致实际结果或表现与这些前瞻性声明中表达或暗示的结果有重大不同。</p>
<p>这些风险和不确定性包括但不限于在会议上获得法定人数的延迟或挑战，包括对会议法定人数或会议本身的有效性提出质疑的索赔或诉讼的可能性。上述因素的清单并不详尽。您应仔细考虑上述因素以及公司最终招股说明书（文件编号 333-298285）中 “风险因素” 部分描述的其他风险和不确定性，该招股说明书于 2025 年 11 月 3 日向证券交易委员会（“SEC”）提交，以及 Psyence BioMed 不时向 SEC 提交的其他文件。</p>
<p>这些文件识别并解决了可能导致实际事件和结果与前瞻性声明中包含的内容有重大不同的其他重要风险和不确定性。实际结果和未来事件可能与这些声明中预期的结果有重大不同。本通讯中的任何内容不应被视为任何人对前瞻性声明将实现的陈述，或对这些前瞻性声明所设想的任何结果将实现的陈述。您不应对前瞻性声明过度依赖，这些声明仅在作出时有效。除法律要求外，Psyence BioMed 不打算更新这些前瞻性声明。</p>
<p>公司不对其拟议产品的医疗、治疗或健康益处做出任何声明。美国食品和药物管理局、加拿大卫生部或其他类似监管机构尚未评估关于裸盖菇素、裸盖菇素类似物或其他迷幻化合物或营养保健产品的声明。这些产品的有效性尚未通过授权的临床研究确认。不能保证裸盖菇素、裸盖菇素类似物或其他迷幻化合物或营养保健品的使用能够诊断、治疗、治愈或预防任何疾病或状况。需要进行严格的科学研究和临床试验。公司的产品候选者是实验性的，尚未获得任何监管机构的批准用于治疗任何疾病或状况，且临床结果（如有）可能无法指示未来的结果。任何关于潜在产品的质量、一致性、有效性和安全性的引用并不意味着公司在临床试验中已验证这些内容，或公司将完成这些试验。如果公司无法获得商业化其业务所需的批准或研究，可能会对公司的业绩和运营产生重大不利影响。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1Ea3lNaU0zTXpjMk5EVTRJekl5T0RVNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1Ea3lNaU0zTXpjMk5EVTRJekl5T0RVNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/N2Q4NWQxZGUtNzA1Yi00MTMxLWI1OWItMzllMWE2ZWVhM2QzLTEyOTc0NjctMjAyNi0wMS0yMi1lbg==/tiny/Psyence-Biomedical-Ltd-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/N2Q4NWQxZGUtNzA1Yi00MTMxLWI1OWItMzllMWE2ZWVhM2QzLTEyOTc0NjctMjAyNi0wMS0yMi1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

<p>Psyence Biomedical Ltd.（纳斯达克代码：PBM）宣布，由于缺乏法定人数，其年度和特别股东会议将推迟至 2026 年 2 月 12 日。会议将在南非开普敦的纽约时间上午 9:00 举行。记录日期保持不变，为 2025 年 12 月 23 日。公司正在与代理机构合作，以确保重新召开的会议达到法定人数。Psyence BioMed 专注于基于迷幻药的治疗，旨在满足未被满足的心理健康需求</p>

<p>NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ <strong>Psyence BioMed</strong>” or the “ <strong>Company</strong>”) today announced that it adjourned its annual and special meeting of shareholders (the “ <strong>Meeting</strong>”) until February 12, 2026.</p>
<div class="lb-trans"><p>纽约，2026 年 1 月 22 日（全球新闻稿）——Psyence Biomedical Ltd.（纳斯达克：PBM）（“ <strong>Psyence BioMed</strong>” 或 “ <strong>公司</strong>”）今天宣布，已将其年度及特别股东会议（“ <strong>会议</strong>”）延期至 2026 年 2 月 12 日。</p>
</div><p>The Meeting will now be held on February 12, 2026, at 9:00 a.m. New York Time/4:00 p.m. Cape Town time at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, South Africa.</p>
<div class="lb-trans"><p>会议将于 2026 年 2 月 12 日上午 9:00（纽约时间）/下午 4:00（开普敦时间）在南非开普敦观察区 Gogosoa 街 51 号，Riverlands，办公大楼 4，Venture Workspace Riverlands 举行。</p>
</div><p>The adjournment is a result of the requisite quorum of shareholders not having been achieved to hold the Meeting. The Company is working with its proxy agents to help ensure that quorum is obtained for the reconvened meeting on February 12, 2026. For details concerning the business of the Meeting, please see the Company’s notice of meeting and management information circular dated January 2, 2026, filed on EDGAR. Please note that the record date for the Meeting, close of business on December 23, 2025, has not changed.</p>
<div class="lb-trans"><p>此次延期是由于未达到召开会议所需的股东法定人数。公司正在与其代理人合作，以确保在 2026 年 2 月 12 日重新召开的会议上达到法定人数。有关会议业务的详细信息，请参见公司于 2026 年 1 月 2 日提交的会议通知和管理信息通函，已在 EDGAR 上备案。请注意，会议的记录日期，即 2025 年 12 月 23 日的营业结束时间，未发生变化。</p>
</div><p><strong>About Psyence BioMed</strong></p>
<div class="lb-trans"><p><strong>关于 Psyence BioMed</strong></p>
</div><p>Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.</p>
<div class="lb-trans"><p>Psyence Biomedical Ltd.（纳斯达克：PBM）是少数几家专注于迷幻药物治疗的多资产、垂直整合的生物制药公司之一。它是第一家专注于开发自然来源（非合成）迷幻药物（如裸盖菇素和伊波卡因）的生命科学生物技术公司，并在纳斯达克上市。我们致力于解决未满足的心理健康需求。我们承诺采用基于证据的方法，开发安全、有效且获得 FDA 批准的自然来源迷幻治疗，适用于广泛的心理健康障碍。</p>
</div><p><strong>Contact Information for Psyence Biomedical Ltd.</strong> Email: ir@psyencebiomed.com</p>
<div class="lb-trans"><p><strong>Psyence Biomedical Ltd.的联系信息</strong> 电子邮件：ir@psyencebiomed.com</p>
</div><p>Media Inquiries: media@psyencebiomed.com</p>
<div class="lb-trans"><p>媒体咨询：media@psyencebiomed.com</p>
</div><p>General Information: info@psyencebiomed.com</p>
<div class="lb-trans"><p>一般信息：info@psyencebiomed.com</p>
</div><p><strong>Investor Contact:</strong> Michael Kydd</p>
<div class="lb-trans"><p><strong>投资者联系：</strong> Michael Kydd</p>
</div><p>Investor Relations Advisor</p>
<div class="lb-trans"><p>投资者关系顾问</p>
</div><p>michael@psyencebiomed.com</p>
<div class="lb-trans"><p>michael@psyencebiomed.com</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.</p>
<div class="lb-trans"><p>本通讯包含 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”。此类声明包括但不限于关于未来财务和运营结果、我们的计划、目标、期望和意图的声明，以及其他以 “可能导致”、“预计”、“将继续”、“预期”、“估计”、“相信”、“打算”、“计划”、“预测”、“展望” 或类似含义的词语标识的声明。</p>
</div><p>Forward-looking statements in this communication include statements regarding the reconvening of the Meeting and the timing (if any) of the Meeting. These statements are based on current assumptions and expectations, including that the Company will succeed in obtaining quorum for the reconvened Meeting. These assumptions may prove incorrect. There can be no assurance that the Company will be able to obtain quorum at the reconvened Meeting. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本通讯中的前瞻性声明包括关于会议重新召开的声明及会议的时间（如有）。这些声明基于当前的假设和期望，包括公司将在重新召开的会议上成功获得法定人数的假设。这些假设可能被证明是错误的。不能保证公司能够在重新召开的会议上获得法定人数。存在许多风险和不确定性，可能导致实际结果或表现与这些前瞻性声明中表达或暗示的结果有重大不同。</p>
</div><p>These risks and uncertainties include, among other difficulties, delays or challenges in obtaining quorum for the Meeting, including the possibility of claims or proceedings challenging the validity of quorum for the Meeting or the Meeting itself. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.</p>
<div class="lb-trans"><p>这些风险和不确定性包括但不限于在会议上获得法定人数的延迟或挑战，包括对会议法定人数或会议本身的有效性提出质疑的索赔或诉讼的可能性。上述因素的清单并不详尽。您应仔细考虑上述因素以及公司最终招股说明书（文件编号 333-298285）中 “风险因素” 部分描述的其他风险和不确定性，该招股说明书于 2025 年 11 月 3 日向证券交易委员会（“SEC”）提交，以及 Psyence BioMed 不时向 SEC 提交的其他文件。</p>
</div><p>These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.</p>
<div class="lb-trans"><p>这些文件识别并解决了可能导致实际事件和结果与前瞻性声明中包含的内容有重大不同的其他重要风险和不确定性。实际结果和未来事件可能与这些声明中预期的结果有重大不同。本通讯中的任何内容不应被视为任何人对前瞻性声明将实现的陈述，或对这些前瞻性声明所设想的任何结果将实现的陈述。您不应对前瞻性声明过度依赖，这些声明仅在作出时有效。除法律要求外，Psyence BioMed 不打算更新这些前瞻性声明。</p>
</div><p>The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company’s product candidates are investigational and have not been approved by any regulatory authority for use in the treatment of any disease or condition, and clinical results (if any) may not be indicative of future results. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.</p>
<div class="lb-trans"><p>公司不对其拟议产品的医疗、治疗或健康益处做出任何声明。美国食品和药物管理局、加拿大卫生部或其他类似监管机构尚未评估关于裸盖菇素、裸盖菇素类似物或其他迷幻化合物或营养保健产品的声明。这些产品的有效性尚未通过授权的临床研究确认。不能保证裸盖菇素、裸盖菇素类似物或其他迷幻化合物或营养保健品的使用能够诊断、治疗、治愈或预防任何疾病或状况。需要进行严格的科学研究和临床试验。公司的产品候选者是实验性的，尚未获得任何监管机构的批准用于治疗任何疾病或状况，且临床结果（如有）可能无法指示未来的结果。任何关于潜在产品的质量、一致性、有效性和安全性的引用并不意味着公司在临床试验中已验证这些内容，或公司将完成这些试验。如果公司无法获得商业化其业务所需的批准或研究，可能会对公司的业绩和运营产生重大不利影响。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1Ea3lNaU0zTXpjMk5EVTRJekl5T0RVNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYzMDkyMiM3Mzc2NDU4IzIyODU5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/N2Q4NWQxZGUtNzA1Yi00MTMxLWI1OWItMzllMWE2ZWVhM2QzLTEyOTc0NjctMjAyNi0wMS0yMi1lbg==/tiny/Psyence-Biomedical-Ltd-.png" alt="" original-src="https://ml.globenewswire.com/media/N2Q4NWQxZGUtNzA1Yi00MTMxLWI1OWItMzllMWE2ZWVhM2QzLTEyOTc0NjctMjAyNi0wMS0yMi1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

Psyence BioMed 宣布推迟2026年1月22日的年度及特别股东大会 | PBM 股票新闻